CGRP Biologics

With Emgality™ approved for Migraine prevention, patients have more choices.
Emgality™ Approved for Migraine Prevention in Adults

It's good news for Migraine patients as Eli Lilly and Company's Emgality™ (galcanezumab-gnlm) became the third new CGRP monoclonal antibody approved by the FDA for Migraine Prevention in Adults. With Emgality™ approved for Migraine prevention, patients have choices of preventive treatments were developed specifically for Migraine.Read More →
Side-by-Side Comparison of Aimovig, Ajovy, and Emgality

Comparing CGRP blockers is the next big challenge for Migraine patients. Now that we have three new preventive options specifically designed for Migraine, we’re faced with that all-important question: Which one should we choose: Aimovig, Ajovy, or Emgality?Read More →
Aimovig™ for Migraine prevention

It's a big day for people living with Migraine disease. For the first time in history, we have a treatment that was specifically developed to prevent Migraine attacks. Aimovig™ (erenumab-aooe) received FDA approval for the prevention of Migraine in patients experiencing four or more Migraine days per month. Read More →